CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
B	BIRC5	NUCLEAR EXPRESSION	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Platinum Compound,Taxane Compound	Wu et al., 2014
B	TP53	Wildtype	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Capecitabine,Cetuximab,Oxaliplatin	Sclafani et al., 2014
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Yang et al., 2012
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Yang et al., 2012
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Rosell et al., 2012
B	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Rosell et al., 2012
B	PIK3CA	Mutation	Predictive	Does Not Support	Sensitivity/Response	Endometrial Cancer	Ridaforolimus,Temsirolimus	Mackay et al., 2014
B	PTEN	Loss	Predictive	Does Not Support	Resistance	Endometrial Cancer	Ridaforolimus,Temsirolimus	Mackay et al., 2014
D	NAPRT	Promoter Hypermethylation	Predictive	Supports	Sensitivity/Response	Cancer	GNE-617	Shames et al., 2013
D	ZEB1	Expression	Predictive	Supports	Sensitivity/Response	Mantle Cell Lymphoma	Doxorubicin,Salinomycin	Sánchez-Tilló et al., 2014
D	PTP4A3	OVEREXPRESSION	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Al-Aidaroos et al., 2013
B	TYMS	Amplification	Predictive	Supports	Resistance	Lung Adenocarcinoma	Pemetrexed	Kasai et al., 2013
B	TP53	Wildtype	Predictive	Supports	Sensitivity/Response	Esophageal Carcinoma	Chemotherapy	Zhang et al., 2013
B	TYMS	Underexpression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pemetrexed	Chen et al., 2011
B	EGFR	Amplification	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab	Personeni et al., 2008
B	TOP1	EXPRESSION	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Irinotecan	Kostopoulos et al., 2009
B	KRAS	Exon 2 Mutation	Predictive	Does Not Support	Resistance	Pancreatic Carcinoma	Erlotinib	Boeck et al., 2013
B	KRAS	Exon 2 Mutation	Prognostic	Supports	Poor Outcome	Pancreatic Carcinoma		Boeck et al., 2013
B	TYMS	Overexpression	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Pemetrexed	Shimizu et al., 2012
B	EGFR	Y1092 PHOSPHORYLATION	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Wang et al., 2012
D	CFLAR	EXPRESSION	Predictive	Supports	Resistance	Prostate Cancer	Bicalutamide	McCourt et al., 2012
D	DUSP6	EXPRESSION	Predictive	Supports	Sensitivity/Response	Cancer	Trametinib	Jing et al., 2012
B	BRCA1	Underexpression	Predictive	Supports	Sensitivity/Response	Ovarian Cancer	Taxane Compound,Platinum Compound	Carser et al., 2011
B	v::ALK	Fusion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Pemetrexed	Lee et al., 2011
B	DNMT1	EXPRESSION	Predictive	Supports	Resistance	Gastric Adenocarcinoma	Cisplatin	Mutze et al., 2011
D	KRAS	Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab,Dasatinib	Dunn et al., 2011
D	ABCC3	Amplification	Predictive	Supports	Resistance	Breast Cancer	Monomethyl Auristatin E,Paclitaxel	O'Brien et al., 2008
D	ABCC10	Overexpression	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Paclitaxel	Oguri et al., 2008
B	EGFR	Overexpression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Dziadziuszko et al., 2006
B	PTEN	Expression	Predictive	Supports	Sensitivity/Response	Breast Cancer	Trastuzumab	Fujita et al., 2006
C	ERBB2	Kinase Domain Mutation	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	De Grève et al., 2012
D	ERBB2	Y772_A775DUP	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib,Sirolimus	Perera et al., 2009
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Afatinib	Lin et al., 2012
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Cross et al., 2014
B	EGFR	C797S	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Osimertinib	Thress et al., 2015
B	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Sequist et al., 2016
B	EGFR	VIII	Predictive	Supports	Sensitivity/Response	Glioblastoma	Rindopepimut	Schuster et al., 2015
B	ERBB2	SERUM LEVELS	Prognostic	Supports	Poor Outcome	Breast Cancer		Lee et al., 2016
B	THBS2	UNDEREXPRESSION	Prognostic	Supports	Poor Outcome	Colorectal Cancer		Lin et al., 2015
B	TERT	Promoter Mutation	Diagnostic	Supports	Positive	Brain Glioma		Yuan et al., 2016
B	HLA-DRA	EXPRESSION	Predictive	Supports	Sensitivity/Response	Skin Melanoma	Nivolumab,Atezolizumab,Pembrolizumab	Johnson et al., 2016
B	KRAS	G12V	Prognostic	Supports	Poor Outcome	Lung Non-small Cell Carcinoma		Renaud et al., 2015
B	KRAS	G12/G13	Predictive	Does Not Support	Sensitivity/Response	Pancreatic Adenocarcinoma	Trametinib	Infante et al., 2014
B	KRAS	Mutation	Predictive	Does Not Support	Resistance	Lung Non-small Cell Carcinoma	MEK Inhibitor RO4987655	Zimmer et al., 2014
D	NRAS	Q61K	Predictive	Supports	Sensitivity/Response	Neuroblastoma	Binimetinib,Everolimus	Kiessling et al., 2016
D	KRAS	Mutation	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Selumetinib,Teprotumumab	Ebi et al., 2011
D	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Breast Cancer	Trastuzumab,Lapatinib	Xia et al., 2005
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Afatinib	Cortés et al., 2015
B	ERBB2	Amplification	Predictive	Supports	Sensitivity/Response	Her2-receptor Positive Breast Cancer	Afatinib,Trastuzumab	Ring et al., 2015
D	v::NTRK1	Fusion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Larotrectinib,Lestaurtinib,Crizotinib	Vaishnavi et al., 2013

Page 32 of 96

Previous Next